|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities | |||||
| Net loss | |||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||
| Stock-based compensation | |||||
| Change in fair value of warrant liability | |||||
| Changes in operating assets and liabilities: | |||||
| Advances on research and development contract services | |||||
| Prepaid expenses and other current assets | |||||
| Prepaid insurance | |||||
| Interest receivable | |||||
| Accounts payable and accrued expenses | |||||
| Research and development contract liabilities | |||||
| Accrued legal settlement | |||||
| Net cash used in operating activities | |||||
| Cash flows from financing activities | |||||
| Proceeds from issuance of common shares from ATM, net of costs | |||||
| Net proceeds from issuance of common stock | |||||
| Proceeds from issuance of common shares from warrant inducement, net of costs | |||||
| Exercise of pre-funded warrants | |||||
| Net cash provided by financing activities | |||||
| Net increase in cash | |||||
| Cash, beginning of year | |||||
| Cash, end of year | |||||
| Noncash investing and financing activities | |||||
| Options issued to settle accrued bonus | |||||
| Deemed dividend – warrant inducement | |||||
| Extinguishment of warrant liability upon exercise of warrants | |||||
| Issuance of shares upon cashless exercise of warrants | |||||
Loading...